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Editorial
In an ideal situation, every person should ‘receive his or 
her share of health care’. However, reality does not often 
match the ideal. Resources are finite while human beings 
have infinite wants and needs. Although it has been said 
that ‘health is priceless’, it certainly has its costs.
The discussion regarding the inequity between how 
much needs to be invested in health care and the avail-
ability of resources has been a constant throughout the 
ages. Only the effort and the ingenuity of our public health 
administrators have managed to narrow this gap. Despite 
the difficulties in obtaining resources, it has been possible 
to achieve certain advances in health care: there is a steady 
increase in longevity and quality of life; rehabilitation has 
succeeded in helping people with disabilities recuperate 
functionally and professionally; and the cure rate has 
increased in various clinical situations.
However, there is almost constantly a certain tension 
between consumers and health administrators, leading to 
a confrontation between the government, which prefers 
cheaper medications, and consumers, who prefer medi-
cations that are more effective. Given the complexity of 
such decisions, it was natural that a new science combining 
the principles of economics with those of medicine should 
arise: health economics, also known as pharmacological 
economics, or pharmacoeconomics.(1,2) The basic principle 
of this new science is not to economize but to generate 
knowledge regarding how to make the best use of health 
resources while taking into account the needs of the commu-
nity. Pharmacoeconomics, to some extent, is based on the 
fact that people need to make decisions about health care 
and want to know the worth of such decisions, as well as on 
the knowledge that bad decisions are generally costly.
Pharmacoeconomics, in its current form, was conceived 
in 1978, when three professors of pharmacy at the University 
of Minnesota - McGhan, Rowland and Bootman - began 
to evaluate and to teach the concepts of cost-effective-
ness of using aminoglycosides in burned patients. However, 
the term pharmacoeconomics was first used in 1986, by 
Townsend.(2)
In Brazil, socioeconomic inequality and strong govern-
mental interference, together with gross technical and 
administrative inefficiency, provide the context for health 
care. This triad draws attention to the importance of 
achieving maximal efficiency in the use of material, human, 
and financial resources in order to generate savings.
The allocation of medical resources creates the need 
to determine the safety, efficacy, and effectiveness of 
any planned intervention. Efficacy is defined as positive 
functioning of the intervention under ideal conditions. 
Effectiveness is the positive functioning of the intervention 
under the day-to-day conditions in which the patient lives. 
A medication might have an excellent effect when it is given 
to the patient under ideal conditions, such as in the hospital 
or in the outpatient clinic, but can lose that advantage if 
the patient stops taking it due to its cost or side effects. In 
such cases, an economic analysis is important. Those two 
concepts are also accompanied by the concept of efficiency 
through the question: “Are we achieving the best benefit 
from the resources we are using?”(1)
When two or more strategies are compared, their bene-
fits and costs should be considered. Therefore, various types 
of economic analyses can be carried out. The simplest way 
to evaluate the appropriateness of a new proposal is illus-
trated in Figure 1. The ideal model is one in which the 
benefits are equal to or greater than the costs.
However, in an economic analysis, the possibilities of 
achieving a greater benefit even at a higher cost or of 
achieving a smaller benefit at a lower cost should also be 
considered.
There are four types of economic analyses: cost-minimi-
zation, cost-effectiveness, cost-utility, and cost-benefit.(1,2)
In the cost-minimization analysis, the prices of two inter-
ventions producing equal benefits are directly compared. 
This is a quite uncommon type of analysis, since it is almost 
impossible to have two interventions producing exactly 
equal results in medicine.
The most common type of analysis in medicine is the 
cost-effectiveness analysis. It compares the effectiveness 
of treatments producing the same outcomes. If one of the 
treatments is cheaper and has a better outcome, the choice 
is obvious. If one of the treatments is more effective but 
more expensive, the treatment presenting the lowest cost 
per outcome is preferred. This type of analysis cannot be 
used to compare different diseases or programs. Therefore, 
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the objective of this type of analysis is to indicate 
the therapeutic option through which it is possible 
to achieve the best clinical result per monetary unit 
applied.
The cost-utility analysis seeks to consider the 
patient satisfaction with the treatment or interven-
tion used rather than the direct results or outcomes 
provided by the medication. Patients are often 
displeased with the side effects of antineoplastic 
drugs. In this case, appropriate tools can evaluate, 
for example, the health-related quality of life. This 
type of analysis was little used until recently. The 
concept of the unit of measure known as quality-
adjusted life years, which associates remaining 
lifetime with the best possible quality of life, has 
been recently introduced. It is necessary to define 
whether it is more beneficial to the patient to have 
increased survival and a lower quality of life or vice 
versa.
Cost-benefit analysis is often confused with 
cost-effectiveness analysis. Cost-benefit analysis 
seeks to identify the treatment option that makes it 
possible to reduce costs or to increase profits. This 
is a quite rare type of analysis in medicine, since it 
puts a price on the life of the patient, which is not 
ethically acceptable.
This issue of the Brazilian Journal of Pulmonology 
features an interesting study evaluating the impact 
of a free program for asthma patients that has 
much to do with pharmacoeconomics. The program 
proved to be highly cost-effective. An analysis of 
the quality of life of these patients would surely 
show that the program has a favorable cost-effec-
tiveness ratio.
Pontes et al.(3) evaluated 269 patients suspected 
of having severe asthma after they had received 
free treatment with an inhaled corticosteroid and a 
short-acting β2 agonist. The patients participated in 
the Bahia State Asthma and Allergic Rhinitis Control 
Program, whose objective is to be comprehensive 
and to benefit a substantial number of patients 
with asthma and rhinitis in that state. The results 
achieved are comparable to those obtained in other 
areas of Brazil, making us believe that patients with 
asthma respond in a quite homogeneous manner, 
regardless of where they live.(4)
The initial results after a one-year follow-up 
period are quite favorable: the number of courses of 
corticosteroids was reduced to one-third in relation 
to the previous year; the number of days missed 
from work or school per patient-year was reduced 
from 11.36 to 1.60; and the number of emergency 
room visits dropped to one-ninth of that observed 
in the preceding year. The authors conclude that 
a program designed to control severe asthma in 
outpatient clinics can lead to a pronounced reduc-
tion in the demand for health resources.
This study proves, once again, what has long 
been taught in medical school: chronic diseases 
require continuous follow up, with uninterrupted 
treatment. Unfortunately, our health policies have 
not prioritized this type of treatment. Asthma is a 
chronic inflammatory disease and requires contin-
uous anti-inflammatory treatment. However, few 
Brazilians have the means to afford the medications. 
The result of this policy is that an overwhelming 
number of patients seek emergency room treatment 
and miss school or work. This leads us to the summa-
tion of two costs evaluated in pharmacoeconomics: 
the direct costs (those that are directly associated 
with the intervention, such as the purchase of 
medications to treat the asthma attacks, the costs 
of hospitalizations/additional examinations, and the 
salaries of the professionals involved in the treat-
ment); and the indirect costs (school or work days 
missed by patients and companions, together with 
the transportation costs related to emergency room 
visits). In the area of health, we still have what 
are known as intangible costs, such as personal 
or familial suffering, which are quite difficult to 
measure.
Unfortunately, Pontes et al.(3) did not stratify 
the patients according to severity, use of resources 
in the previous year and the response to treat-
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Figure 1 - Economic analysis in health.
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ment. It would be interesting to know whether 
the patients having visited the emergency room a 
greater number of times, and therefore presum-
ably presenting a higher degree of inflammation, 
required higher doses of oral or inhaled corticoster-
oids. Although we have treated most patients with 
doses of corticosteroid that are practically fixed, it 
is possible that the treatment can be individual-
ized and that a substantial number of patients can 
receive lower doses of medications, thereby reducing 
the costs. This measure is always quite welcome by 
the authorities involved in the funding of projects 
such as this.
It would have been interesting if the authors had 
classified their cases as ‘uncontrolled’, ‘controlled’, 
‘well controlled’, or ‘totally controlled’. The clas-
sification of asthma as intermittent or persistent 
has never been extremely useful for the orienta-
tion of the treatment team. Asthma has frequently 
been classified as persistent only during the period 
in which the patient was not receiving the proper 
medication. In such cases, upon receiving the 
recommended treatment, the patient with persistent 
asthma became a patient with intermittent asthma, 
and the orientation was for a milder treatment, 
which made the patient return to the previous 
stage of persistent asthma. Classifying asthma by 
the degree to which it is under control is a more 
practical way of monitoring asthma patients, and 
the updated guidelines of the Global initiative for 
Asthma recommend doing so.
Asthma is considered a public health problem 
in Brazil, where there are more than 350 thousand 
hospitalizations, and approximately 2500 deaths, 
per year.
This number of deaths is apparently small in 
comparison to the more than 30,000 deaths from 
chronic obstructive pulmonary disease or pneu-
monia. However, given the current knowledge and 
safety of the treatment, these deaths are unaccept-
able. A project that could result in all economically 
disadvantaged asthma patients receiving their 
medication would revolutionize the treatment of 
chronic diseases and establish a landmark. There 
are efforts being made to implement the National 
Asthma Plan, discussed in May of 2006 in the city 
of Brasília. These efforts are receiving support from 
several medical societies, including the Brazilian 
Thoracic Society, as well as from patient support 
groups, in collaboration with the Ministry of Health 
Department of Basic Care. This dream is close to 
becoming a reality.(5)
Let us hope that this study by Pontes et al. will 
trigger other studies related to pharmacoeconomics 
in this area or in the area of other chronic respira-
tory diseases in Brazil.
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